The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
- 21 April 2019
- journal article
- research article
- Published by Wiley in Veterinary Dermatology
- Vol. 30 (3) , 201-+
Abstract
Background: Ischaemic dermatopathy represents a heterogenous and poorly‐characterized canine syndrome that is often refractory to conventional immunosuppression. Janus‐kinase inhibitors (JAKinibs) are used for the treatment of various human autoimmune diseases, including dermatomyositis. Oclacitinib is a generally well‐tolerated, veterinary‐approved, nonselective JAKinib that has therapeutic potential as an immunosuppressant.Hypothesis/Objectives: To describe four cases of treatment refractory juvenile‐onset ischaemic dermatopathy that rapidly and durably responded to oclacitinib administration.Animals: Four mixed‐breed dogs, three 9‐month‐old male littermates and one 6‐month‐old female, were presented for generalized patchy alopecia, scarring and ulcerative dermatitis. Microscopic skin lesions were consistent with a severe ischaemic dermatopathy.Methods and materials: A complete remission of skin lesions could not be achieved in any dog with glucocorticoids alone, nor when these were combined with adjuvant immunosuppressants. Oclacitinib treatment was then initiated at the dosage of 0.4‐0.7 mg/kg twice daily, along with a tapering regimen of oral prednisolone.Results: A full clinical remission was achieved within four weeks of starting this combination therapy, with prednisolone being stopped within eight weeks thereof. Remission was maintained in two dogs with lower doses or dosing frequencies of oclacitinib, whereas the two others required persistent twice daily administration of this JAKinib.Conclusions and clinical importance: Oclacitinib was a useful immunosuppressive adjuvant to oral glucocorticoids for the treatment of refractory or severe cases of ischaemic dermatopathy in these four dogs. Such observation warrants further studies of the safety, efficacy and mechanism of action of oclacitinib as an immunosuppressant.Keywords
This publication has 20 references indexed in Scilit:
- Tofacitinib Citrate for Refractory Cutaneous DermatomyositisJAMA Dermatology, 2016
- Integumentary System2016
- The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseasesGene, 2016
- Familiäres Auftreten der Dermatomyositis bei Working KelpiesTierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, 2015
- Dermatomyositis‐like disease in aRottweilerVeterinary Dermatology, 2014
- Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergyJournal of Veterinary Pharmacology and Therapeutics, 2014
- Ischemic DermatopathiesVeterinary Clinics of North America: Small Animal Practice, 2012
- Pathogenesis of Dermatomyositis: Role of Cytokines and InterferonCurrent Rheumatology Reports, 2011
- Interface Diseases of the Dermal‐Epidermal Junction2005
- Vaccine‐induced ischemic dermatopathy in the dogVeterinary Dermatology, 1999